APPENDIX A

This Appendix is circulated to Shareholders of AsiaMedic Limited (the "**Company**") together with the Company's Annual Report. Its purpose is to explain to Shareholders the rationale and provide information relating to the proposed renewal of the Share Purchase Mandate to be tabled at the Annual General Meeting ("**AGM**") to be held on Monday, 29 April 2019, 9.30 a.m. at 350 Orchard Road, #10-01 Shaw House, Singapore 238868.

The Notice of AGM and Proxy Form are enclosed with the Annual Report.

If you are in any doubt about its content or the action you should take, you should consult your legal, financial, tax or other professional advisers immediately.

If you have sold or transferred all your shares in the capital of AsiaMedic Limited (the "**Company**") held through The Central Depository (Pte) Limited ("**CDP**"), you need not forward the Annual Report (and the accompanying appendices (including this Appendix), the Notice of AGM and the Proxy Form) to the purchaser or transferee as arrangements will be made by CDP for the Annual Report (and the accompanying appendices (including this Appendix), the Notice of AGM and the Proxy Form) to be sent to the purchaser or transferee. If you have sold or transferred all your ordinary shares in the Company represented by physical share certificate(s), you should forward the Annual Report (and the accompanying appendices (including this Appendix), the Notice of AGM and the Proxy Form) immediately to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for onward transmission to the purchaser or transferee.

This Appendix has been prepared by the Company and its contents have been reviewed by the Company's sponsor, Xandar Capital Pte Ltd (the "**Sponsor**"), for compliance with the Listing Manual (Section B: Rules of Catalist) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Sponsor has not independently verified the contents of this Appendix including the accuracy or completeness of any of the information disclosed or the correctness of any of the statements made, opinions expressed or reports contained in this Appendix.

This Appendix has not been examined or approved by the SGX-ST. The SGX-ST and the Sponsor assume no responsibility for the contents of this Appendix including the correctness of any of the statements made, opinions expressed or reports contained in this Appendix.

Contact person for the Sponsor: Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd)
Address: 3 Shenton Way, #24-02 Shenton House, Singapore 068805
Telephone number: (65) 6319 4954

ASIAMEDIC LIMITED
(Registration Number: 197401556E)
(Incorporated in the Republic of Singapore on 29 August 1974)

APPENDIX IN RELATION TO THE PROPOSED RENEWAL OF THE SHARE PURCHASE MANDATE

SUMMARY SHEET FOR RENEWAL OF SHARE PURCHASE MANDATE

(A) Shares purchased in the previous twelve months

The Company did not undertake any share purchases in the previous twelve months pursuant to the Share Purchase Mandate obtained at the annual general meeting of the Company on 23 April 2018.

(B) Renewal of the Share Purchase Mandate

The Ordinary Resolution No. 8 if passed at the AGM, will renew the Share Purchase Mandate from the date of the AGM until: (i) the date that the next annual general meeting of the Company is held; (ii) the date that the next annual general meeting of the Company is required by law to be held; (iii) the date on which the authority conferred by the Share Purchase Mandate is revoked or varied; or (iv) the date on which purchases and acquisitions of the Company's shares ("**Shares**") pursuant to the Share Purchase Mandate are carried out to the full extent mandated, whichever is the earliest.

(C) Rationale for the Share Purchase Mandate

Short-term speculation may at times cause the market price of the Shares to be depressed below the true value of the Company and its subsidiaries (the "**Group**"). The renewal of the Share Purchase Mandate will provide the Directors with the means to restore investors' confidence and to protect existing Shareholders' investments in the Company in a depressed share-price situation through judicious share purchases to enhance the earnings per Share and/or the net asset value per Share. The share purchases will enhance the net asset value per Share if the share purchases are made at a price below the net asset value per Share.

The Share Purchase Mandate will also provide the Company with an expedient and cost-effective mechanism to facilitate the return of surplus cash reserves to the Shareholders, as and when the Directors are of the view that this would be in the best interests of the Company and the Shareholders.

The Directors will only make a share purchase as and when the circumstances permit and only if the Directors are of the view that such purchases are in the best interests of the Company and the Shareholders. The Directors will decide whether to purchase Shares only after taking into account, among other things, the market conditions at such time, the Company's financial condition and whether the Company will remain solvent (as defined by Section 76F(4) of the Companies Act, Chapter 50 of Singapore (the "**Act**")) as a result of such purchases, and whether such purchases represent an efficient and cost-effective approach to enhance share value. Share purchases will only be made if the Directors believe that such purchases are likely to benefit the Company and increase economic value for Shareholders.

The Directors will ensure that the share purchases will not have any effect on the Shares listed on the Catalist of the SGX-ST ("**Catalist**"). Rule 723 of the Listing Manual of the SGX-ST, Section B: Rules of Catalist (the "**Catalist Rules**") requires at least ten per cent. (10%) of the total number of issued shares in any class of a company's listed securities to be held by the public at all times. The Directors shall safeguard the interests of public Shareholders before undertaking any share purchases. Before exercising the Share Purchase Mandate, the Directors shall at all times take due cognizance of (a) the then shareholding spread of the Company in respect of the number of Shares held by substantial shareholders and by non-substantial shareholders; and (b) the volume of trading on Catalist in respect of the Shares immediately before the exercise of any share purchase.

As at 22 March 2019, (the "**Latest Practicable Date**"), the total number of issued and paid-up Shares of the Company is 390,588,125 (including 100,000 Shares held by the Company as treasury shares). Currently, 285,556,729 Shares (73.13%) of a total of 390,488,125 Shares issued by the Company (excluding treasury shares) are held by the public. The Company is of the view that there is sufficient number of Shares held by public Shareholders, which would permit the Company to undertake share purchases of up to ten per cent. (10%) of its total number of issued Shares (excluding treasury shares) without affecting the listing status of the Shares on Catalist. The Company will ensure that the share purchases will not cause market illiquidity or affect orderly trade or adversely affect the financial condition of the Company.

(D) Financial impact of the proposed share purchases

1. The purchased Shares may be:

   (i) held by the Company; or

   (ii) dealt with, at any time, in accordance with Section 76K of the Act, as treasury shares.

   Section 76K of the Act allows the Company to:

   (i) sell the Shares (or any of them) for cash;

   (ii) transfer the Shares (or any of them) for the purposes of or pursuant to any share scheme, whether for employees, directors or other persons;

   (iii) transfer the Shares (or any of them) as consideration for the acquisition of shares in or assets of another company or assets of a person;

   (iv) cancel the Shares (or any of them); or

   (v) sell, transfer or otherwise use the Shares for such other purposes as may be prescribed by the Minister for Finance.

   The aggregate number of Shares held as treasury shares shall not at any time exceed ten per cent. (10%) of the total number of Shares at that time. Any Shares in excess of this limit shall be disposed of or cancelled in accordance with Section 76K of the Act within six (6) months or such further period as the Registrar of Companies may allow.

   Any purchases of Shares will:

   (i) reduce the amount of the Company's share capital where the Shares were purchased or acquired out of the capital of the Company;

   (ii) reduce the amount of the Company's profits where the Shares were purchased or acquired out of the profits of the Company; or

   (iii) reduce the amount of the Company's share capital and profits proportionately where the Shares were purchased or acquired out of both the capital and the profits of the Company;

   by the total amount of the consideration paid by the Company for the Shares cancelled (including brokerage, commission and other expenses incurred directly in the purchase or acquisition by the Company of its Shares).

The Company cannot exercise any right in respect of treasury shares. In particular, the Company cannot exercise any right to attend or vote at meetings and for the purposes of the Act, the Company shall be treated as having no right to vote and the treasury shares will be treated as having no voting rights. However, the allotment of shares as fully paid bonus shares in respect of treasury shares is allowed. Further, a subdivision or consolidation of any treasury share into treasury shares of a greater or smaller number is allowed so long as the total value of the treasury shares after the subdivision or consolidation is the same as before.

2. The financial effects on the Company and the Group arising from the proposed purchases of the Shares pursuant to the Share Purchase Mandate will depend on, *inter alia*, the aggregate number of Shares purchased and the consideration paid at the relevant time.

3. On the basis of 390,488,125 issued Shares (excluding 100,000 treasury shares) as at the Latest Practicable Date, and assuming no further Shares are issued or repurchased prior to the AGM, the exercise in full of the Share Purchase Mandate of up to a maximum of ten per cent. (10%) of the total number of issued Shares would result in the purchase or acquisition of 38,958,812 Shares.

4. An illustration of the impact of share purchases by the Company pursuant to the Share Purchase Mandate on the Group and the Company's financial position is set out below based on the following assumptions:

   (a) audited financial statements of the Group and the Company for the financial year ended 31 December 2018;

   (b) in full exercise of the Share Purchase Mandate, 38,958,812 Shares were purchased;

   (c) the Maximum Price for the market or off-market purchases is S$0.020 per Share, which is five per cent. (5%) above the average closing prices of the Shares over the last five (5) market days preceding the Latest Practicable Date on which the transactions in Shares were recorded on the SGX-ST;

   (d) no expenses were incurred directly by the Company in the purchase of its Shares;

   (e) the maximum amount of funds required for the share purchases in the aggregate is approximately S$780,000; and

   (f) that the Company holds 39,058,812 treasury shares (being the maximum number of treasury shares that the Company is permitted to hold, pursuant to the Act).

Market purchase or off-market purchase made entirely out of capital and/or profits, and either cancelled or held as treasury shares

	GROUP		COMPANY	
	Before Share Purchase (S$'000)	**After Share Purchase (S$'000)**	**Before Share Purchase (S$'000)**	**After Share Purchase (S$'000)**
As at 31 December 2018				
Total equity	4,377	3,597	267	(513)
Net tangible assets ("**NTA**")[(1)]	3,853	3,073	267	(513)
Current assets	6,499	5,719	3,630	2,850
Current liabilities	4,956	4,956	753	753
Total borrowings	3,708	3,708	3,000	3,000
Cash and short term deposits	2,946	2,166	1,342	562
Number of Shares ('000)	390,488	351,529	390,488	351,529
Financial Ratios				
NTA per Share (cents)	0.99	0.87	0.07	(0.15)
Basic loss per Share (cent)[(2)]	(1.22)	(1.36)	(1.57)	(1.75)
Gearing (times)[(3)]	0.85	1.03	11.24	(5.85)
Current ratio (times)[(4)]	1.31	1.15	4.82	3.78

Notes:

1. NTA equals total equity less goodwill and intangible asset.
2. For illustrative purposes, basic loss per Share is computed based on the loss for the year attributable to owners of the Company divided by number of Shares as shown in the table above.
3. Gearing equals total borrowings divided by total equity.
4. Current ratio equals current assets divided by current liabilities.
5. This is on the assumption that the Share Purchase Mandate is exercised in full. The Directors do not propose to exercise the proposed Share Purchase Mandate to such extent as would result in the Group or the Company being in a negative working capital or negative cash and short term deposits position.

As at 31 December 2018, the Group and the Company had cash and short term deposits of S$2,946,000 and S$1,342,000 respectively. As the share purchases will reduce the cash and short term deposits of the Group and the Company, there will be a corresponding reduction in the current assets and the total equity of the Group and the Company. The current ratios of the Group and the Company will decline. The actual impact on the current ratios will depend on the number of Shares purchased and the prices at which the Shares were purchased.

When undertaking any share purchase, the Directors will ensure that:

(a) the Company and the Group will at all times have adequate working capital to meet its operational requirements;

(b) any share purchase will be financed by the Company's distributable profits and/or capital; and

(c) the Company will not obtain nor incur any borrowings to finance any share purchase.

The Company will not undertake any share purchase if the Company or the Group will have a negative cash and short term deposits position after the share purchase.

5. Shareholders should note that the financial effects set out above are based on the audited financial statements of the Group and the Company for the financial year ended 31 December 2018 and are for illustration only and may not be representative of future performance.

6. The Company intends to use its internal sources of funds to finance its purchases of the Shares. The Company does not intend to obtain or incur any borrowings to finance its purchases of the Shares. The Directors do not propose to exercise the Share Purchase Mandate in a manner and to such extent that the financial condition and working capital requirements of the Group would be materially affected.

7. The Company will take into account both financial and non-financial factors, among other things, the market conditions at such time, the Company's financial condition, the performance of the Shares and whether such share purchases would represent the most efficient and cost-effective approach to enhance the share value. Share purchases will only be made if the Directors believe that such purchases are likely to benefit the Company and increase economic value for Shareholders.

(E) Consequences of share purchases under the Singapore Code on Take-over and Mergers

1. In accordance with the Singapore Code on Take-over and Mergers (the "**Code**"), a person will be required to make a general offer for a public company if:

(a) his voting rights increases to thirty per cent. (30%) or more of the voting rights of the company; or

(b) he already holds between thirty per cent. (30%) and fifty per cent. (50%) of the voting rights of the company, and he increases his voting rights in the company by more than one per cent. (1%) in any six-month period.

2. As at the Latest Practicable Date, the Directors' and substantial shareholders' interests are as follows:

	Direct Interest No. of Shares	Deemed Interest No. of Shares	Total Interest No. of Shares	Before Share Purchase % [1]	After Share Purchase % [2]
Director					
Tan Soo Kiat [3]	–	8,000,000	8,000,000	2.05	2.28
Substantial Shareholders					
Luye Medical Group Pte. Ltd. [4]	95,431,396	–	95,431,396	24.44	27.15
Luye Medical Investment Pte. Ltd. [5]	–	95,431,396	95,431,396	24.44	27.15
Luye Life Sciences Group Ltd [6]	–	95,431,396	95,431,396	24.44	27.15
Nelumbo Investments Limited [7]	–	95,431,396	95,431,396	24.44	27.15
Ginkgo (PTC) Limited [8]	–	95,431,396	95,431,396	24.44	27.15
Shorea LBG [10]	–	95,431,396	95,431,396	24.44	27.15
The Asoka Trust [9]	–	95,431,396	95,431,396	24.44	27.15
Liu Dianbo [9][10]	–	95,431,396	95,431,396	24.44	27.15
Wang Cuilian [9]	–	95,431,396	95,431,396	24.44	27.15
Aona Liu [9]	–	95,431,396	95,431,396	24.44	27.15
Alina W Liu [9]	–	95,431,396	95,431,396	24.44	27.15

Notes:

(1) Based on 390,488,125 Shares in the issued ordinary share capital of the Company (excluding 100,000 treasury shares) as at the Latest Practicable Date.

(2) For illustrative purposes only, based on 351,529,313 Shares in the issued ordinary share capital of the Company (excluding 39,058,812 treasury shares, being the maximum number of treasury shares the Company may hold in accordance with the Act).

(3) Tan Soo Kiat's deemed interest arises from Shares held in a nominee account.

(4) Luye Medical Group Pte. Ltd. holds its Shares in the Company directly.

(5) Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the Securities and Futures Act (Chapter 289) of Singapore ("**SFA**").

(6) Luye Life Sciences Group Ltd holds 100% of the issued and paid-up share capital of Luye Medical Investment Pte. Ltd. Luye Medical Investment Pte. Ltd. is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

(7) Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

(8) The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

(9) The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

(10) Shorea LBG holds 100% of the issued and paid up share capital of Ginkgo (PTC) Limited and is in turn wholly-owned by Mr Liu Dianbo. Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, each of Shorea LBG and Mr Liu Dianbo are deemed to be indirectly interested in the Shares that Ginkgo (PTC) Limited has an interest in.

In the event the Company undertakes share purchases of up to ten per cent. (10%) of the total number of issued Shares as permitted under the Share Purchase Mandate, it is not expected that the shareholdings and voting rights of any of the Shareholders will be increased to thirty per cent. (30%) or more of the Company's voting rights. Accordingly, no general offer is required to be made pursuant to the Code as a result of share purchases under the Share Purchase Mandate.

The Directors have confirmed that they are not aware of any facts or factors which suggest or imply that any particular person(s) and/or Shareholders are, or may be regarded as parties acting in concert such that their respective interests in voting shares in the capital of the Company should or ought to be consolidated, and consequences under the Code would ensue as a result of a share purchase under the Share Purchase Mandate.

(F) Miscellaneous

1. Any share purchases undertaken by the Company shall be at a price of up to but not exceeding the Maximum Price. The Maximum Price is a sum which shall not exceed the sum constituting five per cent. (5%) above the average closing price of the Shares over the period of five (5) trading days in which transactions in the Shares on the SGX-ST were recorded, in the case of a market purchase, before the day on which such purchase is made, and, in the case of an off-market purchase, immediately preceding the date of offer by the Company, as the case may be, and adjusted for any corporate action that occurs after the relevant five (5) day period.

2. In making share purchases, the Company will comply with the requirements of the Catalist Rules, in particular, Rule 871 with respect to announcement of any share purchases. Rule 871 is reproduced below:

   (1) An issuer must announce any share buy-back as follows:

      (a) In the case of a market acquisition, by 9.00 a.m. on the market day following the day on which it purchased shares,

      (b) In the case of an off-market acquisition under an equal access scheme, by 9.00 a.m. on the second market day after the close of acceptances of the offer.

   (2) The announcement must be in the form of Appendix 8D.

3. Share purchases will be made in accordance with the "Guidelines on Share Purchases" as set out in the Annexure to this Appendix. All information required under the Act relating to the Share Purchase Mandate is contained in the said Annexure.

4. The Catalist Rules do not expressly prohibit any purchase of shares by a listed company during any particular time or times. However, as a listed company would be considered an "insider" in relation to any proposed purchase or acquisition of its shares, the Company will undertake not to purchase or acquire Shares pursuant to the Share Purchase Mandate at any time after a price sensitive development has occurred or has been the subject of a decision until the price sensitive information has been publicly announced. In particular, the Company will not purchase or acquire any Shares during the period commencing one month immediately preceding the announcement of the Company's full-year and half-year results.

(G) Directors' responsibility statement

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this Appendix and confirm after making all reasonable enquiries, that to the best of their knowledge and belief, this Appendix constitutes full and true disclosure of all material facts about the Share Purchase Mandate, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this Appendix misleading. Where information in this Appendix has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this Appendix in its proper form and context.

(H) Directors' recommendation

The Directors, having considered the rationale and benefits of the proposed renewal of the Share Purchaser Mandate, are of the opinion that the proposed renewal of the Share Purchase Mandate is in the best interests of the Company. Accordingly, the Directors recommend that Shareholders vote in favour of Ordinary Resolution No. 8 in relation to the proposed renewal of the Share Purchase Mandate.

(I) Taxation

Shareholders who are in doubt as to their respective tax positions or any tax implications, or who may be subject to tax in a jurisdiction outside Singapore, should consult their own professional tax advisers.

(J) Documents for inspection

Copies of the following documents may be inspected at the registered office of the Company at 350 Orchard Road, #08-00 Shaw House, Singapore 238868 during normal business hours up to and including the date of the AGM:

(a) the existing constitution of the Company;

(b) the audited financial statements of the Group and the Company for the financial year ended 31 December 2018; and

(c) the Annual Report.

(K) Compliance with governing laws, regulations and the constitution

The Company confirms that the terms of the Share Purchase Mandate in the Appendix do not contravene any laws and regulations governing the Company and the constitution of the Company.

ANNEXURE

GUIDELINES ON SHARE PURCHASES

1. Shareholders' approval

(a) Purchases of Shares by the Company must be approved in advance by the Shareholders at a general meeting of the Company, by way of a general mandate.

(a) A general mandate authorising the purchase of Shares by the Company representing up to ten per cent. (10%) of the total number of issued ordinary shares in the capital of the Company (excluding treasury shares) will expire on the earliest of:

(i) the date of the next annual general meeting of the Company;

(ii) the date on which the next annual general meeting of the Company is required by law to be held;

(iii) the date when such mandate is revoked or varied by an Ordinary Resolution of the Shareholders of the Company in general meeting; or

(iv) the date on which purchases and acquisitions of Shares pursuant to the Share Purchase Mandate are carried out to the full extent mandated.

(b) The authority conferred on the Directors by the Share Purchase Mandate to purchase Shares shall be renewed at the next annual general meeting of the Company.

(c) When seeking Shareholders' approval for the renewal of the Share Purchase Mandate, the Company shall disclose details pertaining to the purchases of Shares made during the previous 12 months, including the total number of Shares purchased, the purchase price per Share or the highest and lowest price for such purchases of Shares, where relevant, and the total consideration paid for such purchases.

2. Mode of purchase

Share purchases can be effected by the Company in either one of the following two ways or both:

(a) by way of market purchases of Shares on Catalist, which means a purchase transacted through the ready market; or

(b) by way of off-market acquisitions on an equal access scheme in accordance with Section 76C of the Act.

3. Funding of share purchases

(a) In purchasing the Shares, the Company may only apply funds legally permitted for such purchase in accordance with its constitution, and the relevant laws and regulations enacted or prescribed by the relevant competent authorities in Singapore.

(b) Any purchase by the Company may be made out of capital or profits that are available for distribution as dividends, so long as the Company is solvent (as defined by Section 76F(4) of the Act).

(c) The Company may not purchase its Shares on Catalist for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the SGX-ST.

4. Trading restrictions

The number of Shares which can be purchased pursuant to the Share Purchase Mandate is such number of Shares which represents up to a maximum of ten per cent. (10%) of the total number of issued ordinary Shares (excluding treasury shares) in the capital of the Company as at the date of this annual general meeting of the Company.

5. Price restrictions

Any share purchase undertaken by the Company shall be at the price of up to but not exceeding the Maximum Price at which the Shares can be purchased pursuant to the Share Purchase Mandate, which shall not exceed the sum constituting five per cent. (5%) above the average closing price of the Shares over the period of five (5) trading days in which transactions in the Shares on Catalist were recorded, in the case of a market purchase, before the day on which such purchase is made, and, in the case of an off-market purchase on an equal access scheme, immediately preceding the date of offer by the Company, as the case may be, and adjusted for any corporate action that occurs after the relevant five (5) day period.

6. Off-market purchases

(a) For purchases of Shares made by way of an off-market purchase, the Company shall issue an offer document to all Shareholders. The offer document shall contain, *inter alia*, the following information:

(i) the terms and conditions of the offer;

(ii) the period and procedures for acceptances;

(iii) the reasons for the proposed share purchase;

(iv) the consequences, if any, of share purchase by the Company that will arise under the Code or any other applicable take-over rules;

(v) whether the purchase of Shares, if made, would have any effect on the listing of the Company's securities on Catalist; and

(vi) details of any purchase of Shares made by the Company in the previous 12 months whether through market purchases or off-market purchases, including the total number of Shares purchased, the purchase price per Share or the highest and lowest prices paid for such purchases of Shares, where relevant, and the total consideration paid for such purchases.

(b) All offeree Shareholders shall be given a reasonable opportunity to accept any offer made by the Company to purchase their Shares under the Share Purchase Mandate.

(c) The Company may offer to purchase Shares from time to time under the Share Purchase Mandate subject to the requirement that the terms of any offer to purchase Shares by the Company shall be *pari passu* in respect of all offeree Shareholders save under the following circumstances:

(i) where there are differences in consideration attributable to the fact that an offer relates to Shares with different accrued dividend entitlements;

(ii) where there are differences in consideration attributable to the fact that an offer relates to Shares with different amounts remaining unpaid; and

(iii) where there are differences in an offer introduced solely to ensure that every Shareholder is left with a whole number of Shares.

7. Status of purchased Shares

The purchased Shares shall be cancelled immediately on purchase or acquisition unless held in treasury in accordance with Section 76H of the Act. Section 76H of the Act allows purchased Shares to be:

(i) held by the Company; or

(ii) dealt with, at any time, in accordance with Section 76K of the Act, as treasury shares.

Section 76K of the Act allows the Company to:

(i) sell the Shares (or any of them) for cash;

(ii) transfer the Shares (or any of them) for the purposes of or pursuant to any share scheme, whether for employees, directors or other persons;

(iii) transfer the Shares (or any of them) as consideration for the acquisition of shares in or assets of another company or assets of a person;

(iv) cancel the Shares (or any of them); or

(v) sell, transfer or otherwise use the Shares for such other purposes as may be prescribed by the Minister for Finance.

The aggregate number of Shares held as treasury shares shall not at any time exceed ten per cent. (10%) of the total number of Shares at that time. Any Shares in excess of this limit shall be disposed of or cancelled in accordance with Section 76K of the Act within six (6) months.

Any share purchase will:

(i) reduce the amount of the issued Shares in the capital of the Company where the Shares were purchased or acquired out of the capital of the Company;

(ii) reduce the amount of the Company's profits where the Shares were purchased or acquired out of the profits of the Company; or

(iii) reduce the amount of the Company's share capital and profits proportionately where the Shares were purchased or acquired out of both the capital and the profits of the Company;

by the total amount of consideration paid by the Company for the Shares cancelled (including brokerage and commission incurred directly in the purchase or acquisition by the Company of its Shares).

The Company cannot exercise any right in respect of treasury shares. In particular, the Company cannot exercise any right to attend or vote at meetings and for the purposes of the Act, the Company shall be treated as having no right to vote and the treasury shares will be treated as having no voting rights.

8. Notification to the Accounting and Corporate Regulatory Authority ("ACRA")

(a) Within thirty (30) days of the passing of a Shareholders' resolution to approve any purchase of Shares, the Company shall lodge a copy of such resolution with ACRA.

(b) The Company shall notify ACRA within thirty (30) days of a purchase of Shares. Such notification shall include details of the date of the purchase, the total number of Shares purchased by the Company, the issued Shares in the capital of the Company as at the date of the Shareholders' resolution approving the purchase, the Company's issued Shares in the capital after the purchase and the amount of consideration paid by the Company for the purchase.

9. Announcement required under the Catalist Rules

(a) For purchases of Shares made by way of an off-market purchase, the Company shall announce any acquisition or purchase of Shares in the relevant form prescribed by the SGX-ST from time to time, not later than 9.00 a.m. on the second trading day after the close of acceptances of an offer, or within such time period that may be prescribed by the SGX-ST from time to time.

(b) For purchases of Shares made by way of a market purchase, the Company shall announce any acquisition or purchase of Shares in the relevant form prescribed by the SGX-ST from time to time, not later than 9.00 a.m. on the trading day following the date of market acquisition by the Company, or within such time period that may be prescribed by the SGX-ST from time to time.

10. Suspension of purchase

(a) The Company may not undertake any share purchase prior to the announcement of any price-sensitive information by the Company, until such time as the price sensitive information has been publicly announced or disseminated in accordance with the requirements of the Catalist Rules.

(b) The Company may not effect any purchase of Shares on the SGX-ST during the period commencing one month before the announcement of the Company's half year or full year financial statements, as the case may be, and ending on the date of announcement of the relevant results.